Short answer
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on August 20, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Clover Health published written responses to selected shareholder questions following its Q2 2026 earnings announcement.
CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Clover Health published written responses to selected shareholder questions following its Q2 2026 earnings announcement
- Supplemental responses furnished as Exhibit 99.1 and posted on the investor relations website
- Disclosure signals additional investor engagement but contains no new financial figures in the provided text
Item EX-99.1 · Exhibit EX-99.1
- CA-managed year-3 members generate approximately $155 PMPM more insurance gross profit than year-1 members
- CA-managed members show approximately 18% better MCR in year 3, supporting Clover’s cohort-maturation earnings thesis
- 4.5-Star ratings apply to the 2027 payment year, providing incremental flexibility beyond underlying cohort improvement
- Approximately 49% of membership remains in years one and two, leaving substantial maturation upside but retaining execution risk
- New Jersey individual non-SNP market share is approximately 31%, favoring density-led growth over near-term geographic expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings
Get the next CLOV 8-K as it lands
Follow CLOV for push alerts, or ask the research agent what this filing means.